- Home
- PAM vs PCVX Comparison
PAM vs PCVX Comparison
Compare PAM & PCVX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PAM
- PCVX
- Stock Information
- Founded
- PAM 1945
- PCVX 2013
- Country
- PAM Argentina
- PCVX United States
- Employees
- PAM N/A
- PCVX N/A
- Industry
- PAM Electric Utilities: Central
- PCVX Biotechnology: Pharmaceutical Preparations
- Sector
- PAM Utilities
- PCVX Health Care
- Exchange
- PAM Nasdaq
- PCVX Nasdaq
- Market Cap
- PAM 4.5B
- PCVX 4.0B
- IPO Year
- PAM N/A
- PCVX 2020
- Fundamental
- Price
- PAM $86.66
- PCVX $41.81
- Analyst Decision
- PAM Hold
- PCVX Strong Buy
- Analyst Count
- PAM 2
- PCVX 8
- Target Price
- PAM $92.75
- PCVX $114.17
- AVG Volume (30 Days)
- PAM 520.5K
- PCVX 1.5M
- Earning Date
- PAM 11-04-2025
- PCVX 11-04-2025
- Dividend Yield
- PAM N/A
- PCVX N/A
- EPS Growth
- PAM N/A
- PCVX N/A
- EPS
- PAM 0.33
- PCVX N/A
- Revenue
- PAM $1,875,000,000.00
- PCVX N/A
- Revenue This Year
- PAM $136,919.08
- PCVX N/A
- Revenue Next Year
- PAM $36.38
- PCVX N/A
- P/E Ratio
- PAM $10.74
- PCVX N/A
- Revenue Growth
- PAM N/A
- PCVX N/A
- 52 Week Low
- PAM $54.95
- PCVX $27.66
- 52 Week High
- PAM $97.55
- PCVX $107.31
- Technical
- Relative Strength Index (RSI)
- PAM 71.16
- PCVX 51.58
- Support Level
- PAM $85.00
- PCVX $39.87
- Resistance Level
- PAM $90.00
- PCVX $45.90
- Average True Range (ATR)
- PAM 4.42
- PCVX 1.93
- MACD
- PAM 1.67
- PCVX -0.60
- Stochastic Oscillator
- PAM 86.59
- PCVX 32.20
About PAM Pampa Energia S.A.
Pampa Energia SA and its subsidiaries are engaged in the Energy business, mainly in oil and gas production and power generation. The firm's operating business segments are Oil and Gas, Generation, Petrochemicals, Holding, Transportation, and Others. The company derives the maximum revenue from the oil and gas segment.
About PCVX Vaxcyte Inc.
Vaxcyte Inc is a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases. It is developing broad-spectrum conjugate and novel protein vaccines to prevent or treat bacterial infectious diseases. Its product comprises of Pneumococcal conjugate vaccine. The firm's product candidate consists of VAX-31, VAX-24, VAX-A1, VAX-PG, VAX-GI, and Others.